Tharimmune Shares Surge 32% as FDA Greenlights TH104 NDA Pathway
By ATTN Desk · Editorial oversight: Sean Han
Introduction to THARIMMUNE INC
Tharimmune, Inc. (Nasdaq: THAR) is a clinical-stage biotechnology company developing therapeutic candidates in immunology, inflammation, and oncology. Its lead asset, TH104, is advancing through a 505(b)(2) regulatory pathway for the temporary prophylaxis of respiratory and nervous system depression in military personnel and chemical incident responders exposed to high-potency opioids. The company’s expanded pipeline includes TH104 for chronic pruritus in primary biliary cholangitis (PBC) and TH023, an oral infliximab program targeting autoimmune diseases. An early-stage multispecific biologic platform for solid tumors utilizes proprietary EpiClick™ Technology.
Corporate Structure and Experience
Tharimmune employs between 11 and 50 professionals across research, clinical operations, and corporate functions. Leadership includes executives with prior roles at CorMedix, Goldman Sachs, Salix Pharmaceuticals, and Johnson & Johnson, indicating a combination of expertise in biotechnology, drug development, and finance. The company holds a license agreement with OmniAb, Inc. for antibody discovery technology, and its board and management team have experience guiding multiple biotech firms through regulatory approvals and capital raises.
Biotechnology by Sangharsh Lohakare
Recent Developments and News
- August 21, 2025: Shares closed at USD 4.7397, reflecting a reported increase of 32.03% on volume of 6,416,350.
- August 14, 2025: Filed Form 10-Q, covering Q2 2025 financials and operations.
- August 7, 2025: Filed Form 8-K (Items 5.02, 8.01, 9.01), disclosing changes in directors/officers, other corporate events, and exhibits.
- July 31, 2025: Filed Form 8-K (Items 1.01, 9.01), reporting material agreements and financial statement exhibits.
- FDA Feedback: The agency confirmed that no additional clinical trials are required prior to submitting a New Drug Application (NDA) for TH104 under the 505(b)(2) pathway.
- Pipeline Milestones: TH104 is phase 2 ready in the EU and the US, with Chemistry, Manufacturing, and Controls (CMC) plan completion anticipated in 2025 and a planned NDA filing in 2026. TH023 is progressing towards a Phase 1 study.
Financial and Strategic Analysis
Tharimmune’s market capitalization was USD 18.94 million as of August 21, 2025. The company reported a trailing net loss of USD 12.01 million (TTM) and held USD 2.24 million in cash at the most recent quarter end, with a debt-to-equity ratio of 90.99%. No earnings per share or PE ratio is available due to its ongoing pre-revenue status. Strategically, the 505(b)(2) pathway for TH104 is designed to expedite market entry by leveraging existing safety data, while licensing partnerships and the EpiClick™ platform support expansion into autoimmune and oncology indications.
| Metric | Value |
|---|---|
| Share price (08/21/2025) | USD 4.7397 |
| Change (%) | +32.03% |
| Volume | 6,416,350 |
| Market cap | USD 18.94 million |
| Net income (TTM) | −USD 12.01 million |
| Cash (mrq) | USD 2.24 million |
| Debt/Equity (mrq) | 90.99% |
| Beta (5Y monthly) | 1.19 |
Market Position and Industry Context
Tharimmune operates in a competitive biotechnology sector focused on rare diseases and immuno-oncology. With a small-cap profile, the company distinguishes itself through a diversified pipeline and regulatory strategies aimed at reducing clinical risk and development timelines. Partnerships, such as the OmniAb licensing deal, and proprietary technologies position Tharimmune alongside peers addressing unmet needs in PBC, opioid exposure, and solid tumors. Ongoing capital requirements and the outcome of regulatory reviews will be critical factors in market valuation and long-term sustainability.
tl;dr
On August 21, 2025, Tharimmune’s shares rose 32.03% to USD 4.7397. The company filed its Q2 2025 10-Q on August 14 and two 8-K reports on July 31 and August 7, covering corporate changes and material events. FDA feedback confirms that TH104 can proceed to a 505(b)(2) NDA without further trials. Key upcoming milestones include completion of CMC activities in 2025, hepatic impairment study initiation, and a planned NDA submission in 2026.